Zhejiang Hisoar Pharmaceutical Co Ltd (002099):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zhejiang Hisoar Pharmaceutical Co Ltd (002099) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7618
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zhejiang Hisoar Pharmaceutical Co Ltd (Hisoar) is a pharmaceutical company that offers specialty raw materials, preparations, fine chemicals, dyes and intermediates. The company offers raw drugs such as antibody, anti-virus, sugar-reducing, cardiovascular and worm-driven drugs. It produces fine chemicals such as medicine intermediates, active pharmaceutical ingredients and other customized and processed products. The company’s pharmaceutical ingredients comprise cilastatin acid, ethyl 7-chloro-2-oxoheptanoate, beta-methyl vinyl phosphate, beta-methylazetidin-2-one, panipenem, meropenem, faropenem, ertapenem, voglibose, repaglinide, metoprolol succinate, linezolid, sitagliptin phosphate, and rivaroxaban, among others. It markets its products in China and abroad. Hisoar is headquartered in Taizhou, China.

Zhejiang Hisoar Pharmaceutical Co Ltd (002099) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Zhejiang Hisoar Pharma Raises USD154.3 million in Private Placement of Shares 10
Hisoar Pharma Plans to Raise Upto USD328 Million in Private Placement of Shares 11
Debt Offering 12
Zhejiang Hisoar Completes Public Offering Of Bonds Due 2015 For US$47 Million 12
Acquisition 13
Zhejiang Hisoar Pharma Sells 16.1% Stake in Biotechnology Company for USD21.8 Million 13
Zhejiang Hisoar Pharma To Acquire 70% Stake In Suzhou Pharma Company For US$19 Million 14
Zhejiang Hisoar Pharmaceutical Co Ltd – Key Competitors 15
Zhejiang Hisoar Pharmaceutical Co Ltd – Key Employees 16
Zhejiang Hisoar Pharmaceutical Co Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Legal and Regulatory 18
Sep 12, 2018: State Food and Drug Administration: 4 batches of 41 generic drugs passed the consistency assessment 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Hisoar Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zhejiang Hisoar Pharma Raises USD154.3 million in Private Placement of Shares 10
Hisoar Pharma Plans to Raise Upto USD328 Million in Private Placement of Shares 11
Zhejiang Hisoar Completes Public Offering Of Bonds Due 2015 For US$47 Million 12
Zhejiang Hisoar Pharma Sells 16.1% Stake in Biotechnology Company for USD21.8 Million 13
Zhejiang Hisoar Pharma To Acquire 70% Stake In Suzhou Pharma Company For US$19 Million 14
Zhejiang Hisoar Pharmaceutical Co Ltd, Key Competitors 15
Zhejiang Hisoar Pharmaceutical Co Ltd, Key Employees 16

List of Figures
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Zhejiang Hisoar Pharmaceutical Co Ltd (002099):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dentsply Sirona, Inc.:戦略・SWOT・企業財務分析
    Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Career Education Corporation (CECO):企業の財務・戦略的SWOT分析
    Career Education Corporation (CECO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tetra Technologies, Inc.
    Tetra Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tetra Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • International Fibres Group Ltd:企業の戦略的SWOT分析
    International Fibres Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Follett Corporation:企業の戦略・SWOT・財務情報
    Follett Corporation - Strategy, SWOT and Corporate Finance Report Summary Follett Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kawasaki Kisen Kaisha Ltd (9107):石油・ガス:M&Aディール及び事業提携情報
    Summary Kawasaki Kisen Kaisha Ltd (K Line) is a global logistics company. It provides land transportation, air transportation, marine transportation, and harbor transportation. It owns and operates dry bulk carriers, LNG carriers, tankers, car carriers and containerships. The company also provides s …
  • Hubbell Incorporated:企業の戦略・SWOT・財務情報
    Hubbell Incorporated - Strategy, SWOT and Corporate Finance Report Summary Hubbell Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Campofrio Food Group, S.A.:戦略・SWOT・企業財務分析
    Campofrio Food Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary Campofrio Food Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cryo-Cell International Inc (CCEL):企業の財務・戦略的SWOT分析
    Summary Cryo-Cell International Inc (Cryo-Cell) is a cord blood bank service provider. The company offers biotechnology services, collection and preservation of umbilical cord blood stem cells for family use. It provides services such as cord blood banking, cord tissue banking, cord blood and tissue …
  • Aaron’s Inc:戦略・SWOT・企業財務分析
    Aaron's Inc - Strategy, SWOT and Corporate Finance Report Summary Aaron's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Kingsgate Consolidated Limited:企業の戦略・SWOT・財務情報
    Kingsgate Consolidated Limited - Strategy, SWOT and Corporate Finance Report Summary Kingsgate Consolidated Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Citic Resources Holdings Limited:企業の戦略・SWOT・財務分析
    Citic Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Citic Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • The Cumberland Insurance Group:企業の戦略・SWOT・財務情報
    The Cumberland Insurance Group - Strategy, SWOT and Corporate Finance Report Summary The Cumberland Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Biosearch Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biosearch Technologies Inc (Biosearch), a subsidiary of LGC Ltd is a biotechnology company that designs and manufactures regents. The company develops, and manufactures custom oligonucleotide-based tools. Its products include valupanel reagents, fluorogenic probes and primers, stellaries RNA …
  • National Bank of Greece SA:企業の戦略・SWOT・財務情報
    National Bank of Greece SA - Strategy, SWOT and Corporate Finance Report Summary National Bank of Greece SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cape plc:企業の戦略・SWOT・財務情報
    Cape plc - Strategy, SWOT and Corporate Finance Report Summary Cape plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Calibre Group Ltd:企業の戦略・SWOT・財務情報
    Calibre Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Calibre Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Neuland Laboratories Ltd (NEULANDLAB)-製薬・医療分野:企業M&A・提携分析
    Summary Neuland Laboratories Ltd (Neuland Lab), a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company offers APIs in various therapeutic …
  • Re-Vana Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Re-Vana Therapeutics Ltd (Re-Vana) is an ocular pharmaceutical and drug delivery company that develops and commercialization of biodegradable long- acting drug delivery platforms to treat ophthalmic conditions. The company provides drug delivery products such as OcuLief, an injectable platfo …
  • Rowan Companies plc:企業の戦略・SWOT・財務分析
    Rowan Companies plc - Strategy, SWOT and Corporate Finance Report Summary Rowan Companies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆